Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
January 31, 2023 2.971M
October 31, 2022 1.791M
July 31, 2022 1.790M
April 30, 2022 1.789M
January 31, 2022 1.789M
October 31, 2021 1.782M
July 31, 2021 1.780M
April 30, 2021 1.767M
January 31, 2021 1.659M
October 31, 2020 1.259M
July 31, 2020 1.048M
April 30, 2020 1.035M
January 31, 2020 0.4888M
October 31, 2019 0.4855M
July 31, 2019 0.4833M
April 30, 2019 0.0323M
January 31, 2019 0.2937M
October 31, 2018 0.2712M
July 31, 2018 0.2432M
April 30, 2018 0.2359M
January 31, 2018 0.1629M
October 31, 2017 0.1346M
July 31, 2017 0.0983M
April 30, 2017 0.0962M
January 31, 2017 0.0897M
Date Value
October 31, 2016 0.089M
July 31, 2016 0.082M
April 30, 2016 0.0771M
January 31, 2016 0.0771M
October 31, 2015 0.0674M
July 31, 2015 0.0674M
April 30, 2015 0.0561M
January 31, 2015 0.0561M
October 31, 2014 0.0556M
July 31, 2014 0.0556M
April 30, 2014 0.0491M
January 31, 2014 0.0432M
October 31, 2013 0.0388M
July 31, 2013 0.0268M
April 30, 2013 0.0268M
January 31, 2013 0.0268M
October 31, 2012 0.02M
July 31, 2012 0.02M
April 30, 2012 0.02M
January 31, 2012 0.0129M
October 31, 2011 0.0129M
July 31, 2011 0.0129M
April 30, 2011 0.012M
January 31, 2011 0.0156M
October 31, 2010 0.0156M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 172.13M
Alnylam Pharmaceuticals, Inc. 133.73M
Savara, Inc. 205.40M
Vericel Corp. 51.17M
Biogen, Inc. 147.70M